KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Net Income towards Common Stockholders (2016 - 2025)

Nektar Therapeutics has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$34.7 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$34.7 million for Q4 2025, down 578.35% from a year ago — trailing twelve months through Dec 2025 was -$155.3 million (down 30.59% YoY), and the annual figure for FY2025 was -$155.3 million, down 30.59%.
  • Net Income towards Common Stockholders for Q4 2025 was -$34.7 million at Nektar Therapeutics, up from -$35.0 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for NKTR hit a ceiling of $232.8 million in Q4 2023 and a floor of -$159.1 million in Q2 2022.
  • Median Net Income towards Common Stockholders over the past 5 years was -$51.7 million (2023), compared with a mean of -$58.3 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 508.53% in 2023 and later plummeted 578.35% in 2025.
  • Nektar Therapeutics' Net Income towards Common Stockholders stood at -$146.9 million in 2021, then soared by 61.21% to -$57.0 million in 2022, then soared by 508.53% to $232.8 million in 2023, then tumbled by 96.88% to $7.3 million in 2024, then plummeted by 578.35% to -$34.7 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$34.7 million (Q4 2025), -$35.0 million (Q3 2025), and -$39.2 million (Q2 2025) per Business Quant data.